Insider & Cluster Buy Highlights – February 10, 2026
📅 Published: February 10, 2026 at 01:13 PM UTC
1 Cluster Buys5 Insider Purchases
On February 10, 2026, this newsletter featured 1 cluster buy and 5 insider purchases detected from SEC Form 4 filings.
📈 Daily Insider & Cluster Buy Highlights – February 10, 2026
Here are some of the most interesting insider and cluster buying signals from the last 7 days.
⚠️ For information purposes only.
This information is provided for informational purposes only and does not constitute investment advice, financial advice, trading advice, or any other type of advice. All investments carry risk, including the potential loss of principal. Past performance is not indicative of future results. You should consult with a qualified financial advisor, accountant, or other professional before making any investment decisions. The information contained in this newsletter is not intended to be a substitute for professional financial advice.
📊 About Fair Value:
The Fair Value shown for each company is calculated using a Levered Discounted Cash Flow (DCF) model. This method estimates the intrinsic value of a stock by projecting future cash flows and discounting them back to present value, accounting for the company's debt structure. A positive percentage difference indicates the stock may be undervalued relative to this model, while a negative percentage suggests it may be overvalued. Fair value calculations are estimates and should be considered alongside other factors.
🔥 Notable Cluster Buys (≥ $500,000)
Hennessy Capital Investment Corp. VView ChartFinancials
Ticker: HCIC
$10.05
Current Price
52W: Low: $9.70 | High: $10.06
Participants: 3 insiders
Total Shares: 2,013,000
Total Value: $20,130,000
Timeframe: 0 days
Date Range: Feb 06, 2026 to Feb 06, 2026
👥 Participant Details:
HC VIII Sponsor LLC
10% Owner
Date: Feb 06, 2026
671,000 shares
$6,710,000
@ $10.00/share
P&L: +0.5% (+$33,550)
Hennessy Thomas D
Director
Date: Feb 06, 2026
671,000 shares
$6,710,000
@ $10.00/share
P&L: +0.5% (+$33,550)
HENNESSY DANIEL J
Director
Date: Feb 06, 2026
671,000 shares
$6,710,000
@ $10.00/share
P&L: +0.5% (+$33,550)
📈 Average P&L: +0.5% (+33,550)
Current Price: $10.05
📰 Recent News (Last 7 Days):
GlobeNewsWire • Feb 06, 2026
New York, NY, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Hennessy Capital Investment Corp. VIII (NASDAQ: HCICU) (the “Company”), a special purpose acquisition company, announced today the closing of its upsize...
💼 Notable Individual Insider Buys (≥ $100,000)
$5.61
Current Price
$1.12
Fair Value
Transaction Date: Jan 22, 2026
Shares: 5,000,000
Purchase Price: $5.75
Purchase Value: $28,750,000
📉
P&L: 2.4% ($700,000 loss)
📊 Valuation & Analyst Info:
Fair Value: $1.12 (80.1% overvalued vs current price)
Analyst Rating: C-
Avg Price Target: $15.00 (+167.4% vs current)
$14.55
Current Price
Transaction Date: Feb 06, 2026
Shares: 1,437,323
Purchase Price: $18.00
Purchase Value: $25,871,814
📉
P&L: 19.2% ($4,958,764 loss)
📰 Recent News (Last 7 Days):
Seeking Alpha • Feb 06, 2026
Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings. Five IPOs are currently scheduled in the week ahead, and some smaller issuers may join the calendar throughout th...
GuruFocus • Feb 05, 2026
Stock News Amazon lifts 2026 capex to ~$200B: Amazon (AMZN) posted a Q4 EPS miss but revenue beat and guided 2026 capital expenditures to about $200 billion, pr
Reuters • Feb 05, 2026
Shares of drug developer Eikon Therapeutics opened 5.28% below their offer price in their Nasdaq debut on Thursday, valuing the company at about $860.3 million.
Reuters • Feb 04, 2026
Drug developer Eikon Therapeutics said on Wednesday it had raised $381.2 million in its U.S. initial public offering, selling about 21.2 million shares priced at $18 apiece.
$14.55
Current Price
Transaction Date: Feb 06, 2026
Shares: 630,881
Purchase Price: $18.00
Purchase Value: $11,355,858
📉
P&L: 19.2% ($2,176,539 loss)
📰 Recent News (Last 7 Days):
Seeking Alpha • Feb 06, 2026
Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings. Five IPOs are currently scheduled in the week ahead, and some smaller issuers may join the calendar throughout th...
GuruFocus • Feb 05, 2026
Stock News Amazon lifts 2026 capex to ~$200B: Amazon (AMZN) posted a Q4 EPS miss but revenue beat and guided 2026 capital expenditures to about $200 billion, pr
Reuters • Feb 05, 2026
Shares of drug developer Eikon Therapeutics opened 5.28% below their offer price in their Nasdaq debut on Thursday, valuing the company at about $860.3 million.
Reuters • Feb 04, 2026
Drug developer Eikon Therapeutics said on Wednesday it had raised $381.2 million in its U.S. initial public offering, selling about 21.2 million shares priced at $18 apiece.
$5.61
Current Price
$1.12
Fair Value
Transaction Date: Oct 28, 2025
Shares: 1,333,334
Purchase Price: $4.93
Purchase Value: $6,580,003
📈
P&L: 13.7% ($900,000 gain)
📊 Valuation & Analyst Info:
Fair Value: $1.12 (80.1% overvalued vs current price)
Analyst Rating: C-
Avg Price Target: $15.00 (+167.4% vs current)
Cantor EP Holdings VI, LLCView ChartFinancials
10% Owner
Cantor Equity Partners VI, Inc. Class A Ordinary Shares ($CEPS)
$10.15
Current Price
Transaction Date: Feb 06, 2026
Shares: 300,000
Purchase Price: $10.00
Purchase Value: $3,000,000
📈
P&L: 1.5% ($45,000 gain)
📰 Recent News (Last 7 Days):
Seeking Alpha • Feb 06, 2026
Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings. Five IPOs are currently scheduled in the week ahead, and some smaller issuers may join the calendar throughout th...
Business Wire • Feb 06, 2026
NEW YORK--(BUSINESS WIRE)--Cantor Equity Partners VI, Inc. (Nasdaq: CEPS) (the “Company”) announced today that it closed its initial public offering of 11,500,000 Class A ordinary shares at $10.00 per...
Business Wire • Feb 04, 2026
NEW YORK--(BUSINESS WIRE)--Cantor Equity Partners VI, Inc. (Nasdaq: CEPS) (the “Company”) announced today the pricing of its initial public offering of 10,000,000 Class A ordinary shares at $10.00 per...
This newsletter is generated automatically. Please verify all information independently before making investment decisions.
Want to receive these newsletters in your inbox? Sign up here